Drugmaker GSK Chases Volume Over Profit in Africa

Can you mix corporate do-gooding and hard-nosed business? GlaxoSmithKline thinks so. The British drugs giant is having some early success with a novel “hybrid” approach in Africa that is focused on improving drug access by cutting prices for a continent with 24 percent of the world’s health problems and just 1 percent of the budget.
Reuters